Patents by Inventor Carl Henry Behrens

Carl Henry Behrens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthesis and use of kinase inhibitors
    Patent number: 9505719
    Abstract: An improved synthesis of a class of inhibitor of Focal Adhesion Kinase (FAK) is provided, wherein use of an expensive palladium-based catalyst is reduced and reaction yields and product purities are improved. Two key reactions of coupling of aryl halides with anilines are optimized with the surprising discovery that the palladium-based catalyst can be dispensed with entirely in one of the reactions. The invention also provides the use of the FAK-inhibitory compounds in the treatment of inflammatory and immune disorders and of arthritis.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: November 29, 2016
    Assignee: VERASTEM, INC.
    Inventors: Yixiong Lei, Carl Henry Behrens, Hui-Yin Li, Connie L. Sun
  • Aminoindane compounds and use thereof in treating pain
    Patent number: 8865741
    Abstract: The present application provides novel aminoindane compounds and methods for preparing and using these compounds. These compounds are useful in treating pain and/or itch in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) or (II) and a TRPV1 receptor activator. In one embodiment, the TRPV1 receptor activator is lidocaine.
    Type: Grant
    Filed: February 18, 2012
    Date of Patent: October 21, 2014
    Assignee: Asana Biosciences, LLC
    Inventors: Scott Kevin Thompson, Tony Priestley, Roger Astbury Smith, Ashis K. Saha, Sonali Rudra, Arun Kuma Hajra, Dipanwita Chatterjee, Carl Henry Behrens, Yigang He, Hui-Yin Li
  • SYNTHESIS AND USE OF KINASE INHIBITORS
    Publication number: 20140235635
    Abstract: An improved synthesis of a class of inhibitor of Focal Adhesion Kinase (FAK) is provided, wherein use of an expensive palladium-based catalyst is reduced and reaction yields and product purities are improved. Two key reactions of coupling of aryl halides with anilines are optimized with the surprising discovery that the palladium-based catalyst can be dispensed with entirely in one of the reactions. The invention also provides the use of the FAK-inhibitory compounds in the treatment of inflammatory and immune disorders and of arthritis.
    Type: Application
    Filed: August 7, 2013
    Publication date: August 21, 2014
    Applicant: PONIARD PHARMACEUTICALS, INC
    Inventors: Yixiong Lei, Carl Henry Behrens, Hui-Yin Li, Connie L. Sun
  • Aminoindane Compounds and Use Thereof in Treating Pain
    Publication number: 20120214809
    Abstract: The present application provides novel aminoindane compounds and methods for preparing and using these compounds. These compounds are useful in treating pain and/or itch in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) or (II) and a TRPV 1 receptor activator. In one embodiment, the TRPV 1 receptor activator is lidocaine.
    Type: Application
    Filed: February 18, 2012
    Publication date: August 23, 2012
    Inventors: Scott Kevin Thompson, Tony Priestley, Roger Astbury Smith, Ashis K. Saha, Sonali Rudra, Arun Kuma Hajra, Dipanwita Chatterjee, Carl Henry Behrens, Yigang He, Hui-Yin Li
  • Manufacture of water-soluble ?-hydroxynitriles
    Patent number: 6960680
    Abstract: A process for making a water-soluble ?-hydroxynitrile. A 1,2-epoxide and an inorganic cyanide salt are reacted in a solvent having aqueous methanol and a buffer therein to form ?-hydroxynitrile. The buffer substantially inhibits the formation of reaction products other than ?-hydroxynitrile. Optionally, water may be removed from the ?-hydroxynitrile by azeotropic distillation with acetonitrile and subsequently purified via vacuum distillation and filtration.
    Type: Grant
    Filed: January 8, 2003
    Date of Patent: November 1, 2005
    Assignee: Rhodia Chirex, Inc.
    Inventors: Carl Henry Behrens, James Joseph Mencel
  • Manufacture of water-soluble beta-hydroxynitriles
    Publication number: 20040133029
    Abstract: A process for making a water-soluble &bgr;-hydroxynitrile. A 1,2-epoxide and an inorganic cyanide salt are reacted in a solvent having aqueous methanol and a buffer therein to form &bgr;hydroxynitrile. The buffer substantially inhibits the formation of reaction products other than &bgr;hydroxynitrile. Optionally, water may be removed from the &bgr;hydroxynitrile by azeotropic distillation with acetonitrile and subsequently purified via vacuum distillation and filtration.
    Type: Application
    Filed: January 8, 2003
    Publication date: July 8, 2004
    Applicant: Rhodia ChiRex, Inc.
    Inventors: Carl Henry Behrens, James Joseph Mencel
  • Carbocyclic heterocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
    Patent number: 6110910
    Abstract: This invention relates to carbocyclic and heterocyclic fused-ring quinolinecarboxylic acid compounds, to pharmaceutical compositions comprising such compounds, and to methods of using such compounds for the treatment and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, chronic inflammatory diseases, including but not limited to psoriasis and rheumatoid arthritis, and cancer in a mammal.
    Type: Grant
    Filed: November 18, 1998
    Date of Patent: August 29, 2000
    Assignee: Dupont Pharmaceuticals
    Inventors: Ronald Louis Magolda, William John Pitts, Irina Cipora Jacobson, Carl Henry Behrens, Michael James Orwat, Douglas Guy Batt
  • Carbocyclic and hetertocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
    Patent number: 5874441
    Abstract: This invention relates to carbocyclic and heterocyclic fused-ring quinolinecarboxylic acid compounds, to pharmaceutical compositions comprising such compounds, and to methods of using such compounds for the treatment and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, chronic inflammatory diseases, including but not limited to psoriasis and rheumatoid arthritis, and cancer in a mammal.
    Type: Grant
    Filed: March 18, 1997
    Date of Patent: February 23, 1999
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Ronald Louis Magolda, William John Pitts, Irina Cipora Jacobson, Carl Henry Behrens, Michael James Orwat, Douglas Guy Batt
  • (2-quinoxalinyloxy) phenoxypropanoic acids and related derivatives as anticancer agents
    Patent number: 5696119
    Abstract: This invention relates to (2-quinoxalinyloxy)phenoxypropanoic acids, related derivatives thereof, enantiomeric and diastereomeric forms thereof, mixtures of enantiomeric diastereomeric forms thereof, and pharmaceutically acceptable salt forms thereof, pharmaceutical compositions containing them, processes for their preparation, and methods of using them to treat cancer, particularly solid tumors, in mammals.
    Type: Grant
    Filed: December 28, 1994
    Date of Patent: December 9, 1997
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Carl Henry Behrens, Betsy Ann Dusak, Barbara Ann Harrison, Michael James Orwat
  • Carbocyclic and heterocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
    Patent number: 5639759
    Abstract: This invention relates to carbocyclic and heterocyclic fused-ring quinolinecarboxylic acid compounds, to pharmaceutical compositions comprising such compounds, and to methods of using such compounds for the treatment and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, chronic inflammatory diseases, including but not limited to psoriasis and rheumatoid arthritis, and cancer in a mammal.
    Type: Grant
    Filed: March 27, 1995
    Date of Patent: June 17, 1997
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Ronald Louis Magolda, William John Pitts, Irina Cipora Jacobson, Carl Henry Behrens, Michael James Orwat, Douglas Guy Batt